Status:
COMPLETED
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
Lead Sponsor:
Naval Hospital, Athens
Collaborating Sponsors:
National and Kapodistrian University of Athens
Conditions:
Dry Eye
Dry Eye Syndromes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The modern treatment of meibomian gland dysfunction(MGD) is based on anti-inflammatory drops or oral antibiotics for decreasing dry eye disease (DED) associated inflammation, warm compresses for lique...
Eligibility Criteria
Inclusion
- Inclusion criteria were:
- chief complaint of at least one of the following symptoms: dryness, foreign-body sensation, burning, and tearing for 3 months
- diagnosis of DED secondary to MGD with eyelid margin telangiectasias in both eyes
- a baseline Ocular Surface Disease Index (OSDI) score ≥ 40
- tear break-up time (TBUT) ≤ 5 seconds
- corneal fluorescein staining ≥ 6 as per the National Eye Institute (NEI) grading scale for corneal staining.
- Exclusion criteria were:
- history of ocular trauma or surgery
- use of any treatment for DED or MGD other than artificial tears within the past 3 months
- active allergy, infection, or inflammatory disease at the ocular surface unrelated to DED or MGD
- lacrimal drainage system anomalies
- contact lens wear
- use of any systemic or topical anti-inflammatory medicine
Exclusion
Key Trial Info
Start Date :
December 6 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 18 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04425551
Start Date
December 6 2022
End Date
July 18 2025
Last Update
January 2 2026
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Naval Hospital of Athens
Athens, Greece, 11521
2
First Department of Ophthalmology, National and Kapodistrian University of Athens, Athens, Greece
Athens, Greece